Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
... over
D2 receptors. In vivo, ITI-007 produced an
intracellular protein
phosphorylation pattern consistent with ... orally active and a potent inhibitor of a
novel
intracellular target and was designed to amplify but not ... with a proprietary and unique
window into the
intracellular action of Central Nervous System (CNS) drugs
or ...
Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome
... small molecule inhibitor of the immunoproteasome. The proteasome is an
intracellular complex present in most cells that mediates the degradation of
intracellular proteins, including key components of pathways that contribute to cancer ...
Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
... response to increases in blood glucose. The GDIR signals through a similar
intracellular pathway as the GLP-1 receptor, with common downstream effects, but unlike ... stimulation has also been found to increase the levels and activity of
intracellular factors thought to be involved in the preservation of beta cells, and GDIR ...
Parasites That Live Inside Cells Use Loophole to Thwart Immune System
... to live and proliferate within
macrophages themselves. To do so, these
intracellular pathogens deploy an
arsenal of weapons to avoid and counterattack ... nitric oxide. "However, no one had really explored
the possibility that
intracellular pathogens could directly exploit
arginase-activation as a defense until ...
Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
... included synergy
studies, rate of killing, post antibiotic effect and
intracellular activity
against MTB in macrophages.
There were no antagonistic ... and showed increased rate of killing,
enhanced post antibiotic effect and
intracellular killing activity. Results
showed that the SQ109 and TMC207 drug ...
New Data Support Role for Monitoring of Cell-Mediated Immunity in Adult Patients Following Renal Transplantation
... Santander, Spain, used the Cylex
ImmuKnow assay to prospectively monitor
intracellular adenosine
triphosphate (ATP) concentrations following CD4 cell activation ... immune status."
*Sanchez-Velasco P, Rodrigo E, Valero R, et al.
intracellular ATP
concentrations of CD4 cells in kidney transplant patients with and ...
Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
... chemical modification and lipid technologies to achieve
efficient
intracellular uptake without triggering an immune system
response. This approach has ... diseased tissues and cells, whilst increasing their
bioavailability and
intracellular uptake.
In July 2007, Silence Therapeutics formed a research and ...
Pre-Clinical Data Show Intracellular Pathways Affected by ONCONASE(R)
... advisory board,
presented a poster entitled "ONCONASE (ranpirnase):
intracellular Activity
and Extracellular Selectivity." The data demonstrated that 181 ... the genes involved
in triggering apoptosis (programmed cell death) and the
intracellular MAPK
signaling pathway were impacted by ONCONASE in vitro. ...
Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
... at pre-synaptic dopamine
receptors. For example, ITI-007 provoked an
intracellular phosphorylation
pattern consistent with the activity of a partial agonist ... profile provides the Company with a proprietary and unique
window into the
intracellular action of CNS drugs or drug candidates.
Intra-Cellular Therapies uses this ...
Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice
... is unique in its ability to offer tissue specific targeting
of siRNA and
intracellular delivery against the
intracellular machinery of
the target tissue. In addition, Intradigm also developed the ...
Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
... the last twenty-five years indicate that KRAS plays an important role in cell growth regulation. In mCRC, EGFR transmits signals through a set of
intracellular proteins. Upon reaching the nucleus, these signals instruct the cancer cell to reproduce and metastasize, leading to cancer progression. Anti-EGFR ...
R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
... develops novel, small molecule drugs for the treatment of inflammatory/autoimmune diseases and metabolic diseases. Our pioneering research focuses on
intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with ...
Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
... mitochondrial membrane stabilizer and a potent antioxidant.
"Cardax has pioneered a novel approach to treating the source of inflammation,
intracellular oxidative stress," said David G. Watumull, CEO of Cardax. "We believe this to be a new paradigm for the treatment of liver and cardiovascular disease ...
Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
... develops novel, small molecule drugs for the treatment of inflammatory/autoimmune diseases and metabolic diseases. Our pioneering research focuses on
intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with ...
Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
... develops novel, small molecule drugs for the treatment of inflammatory/autoimmune diseases and metabolic diseases. Our pioneering research focuses on
intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with ...
Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
... mediated through the PI3K/PTEN pathway.
About PI3 Kinase
Phosphatidylinositol 3 kinases (PI3K) are involved in one of the major pathways of
intracellular signal transduction and are important in controlling cell growth/angiogenesis, differentiation, proliferation and survival/apoptosis. Dysregulation ...
Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting
... by the meaningful improvements in cardiac function and overall condition of patients, findings that we believe demonstrate the return toward normal
intracellular calcium cycling and contractility in some of the heart muscle cells of these very sick patients," said Krisztina M. Zsebo, Ph.D., president and chief ...
Celladon Corporation Announces Presentation of First-in-Human Gene Transfer to Treat Heart Failure at the 12th Annual Meeting of the American Society of Gene Therapy
... Convention Center.
"A key underpinning of heart failure is the depletion of SERCA2a enzyme in heart muscle cells, which results in abnormal
intracellular calcium cycling and poor contractility," said Zsebo. "Our research shows that recombinant adeno-associated viral vectors (AAV) are ideal for ...
Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting
... mediated through the PI3K/PTEN pathway.
About PI3 Kinase
Phosphatidylinositol 3 kinases (PI3K) are involved in one of the major pathways of
intracellular signal transduction and are important in controlling cell growth/angiogenesis, differentiation, proliferation and survival/apoptosis. Dysregulation ...
Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki
... influenzae , (Poster P 1393). The
second poster contains in vivo data demonstrating that, following oral
administration, NXL103 was able to kill
intracellular drug-resistant and
non-drug-resistant strains of Staphylococcus aureus in infected macrophages,
(Poster P 1025). The final poster shows that NXL103 ...
Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
... novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and metabolic diseases. Our pioneering research focuses on
intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with ...
IBT Laboratories to Launch New Pneumococcal Antibody Avidity Test at AAAAI Meeting, Booth 729
...
IBT will present two scientific posters at the conference:
Saturday, 9:45-10:45 am - # 41: T Cell Immunity Assessed by
intracellular Cytokine Analysis Following Stimulation of Whole Blood or PBMCs with Microbial Antigens of Mitogens
Sunday, 9:45-10:45 am - # 405: Presence ...
Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
... novel, small-molecule drugs for the treatment of
inflammatory/autoimmune diseases and metabolic diseases. Our pioneering
research focuses on
intracellular signaling pathways and related targets that
are critical to disease mechanisms. Rigel's productivity has resulted in
strategic collaborations with ...
Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
... proteins chemically linked at specific sites to phosphates. This profile provides the Company with a proprietary and unique window into the
intracellular action of CNS drugs or drug candidates. Intra-Cellular Therapies uses this platform in its drug discovery and development efforts of proprietary ...
Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
... broad spectrum anti-proliferative activity against diverse cancer cell lines, and the data attribute the anti-tumor activity of CX-4945 to
intracellular inhibition of the CK2 enzyme.
About Cylene Pharmaceuticals, Inc.
Cylene Pharmaceuticals is a biotech pharmaceutical company dedicated to ...
Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351
... Cytarabine:Daunorubicin Ratios Delivered by CPX-351 to Human Leukemia Xenografts is Associated with Liposome-Mediated Bone Marrow Drug Accumulation,
intracellular Delivery of Encapsulated Agents to Leukemia Cells, and Increased Efficacy will be presented on Saturday, December 6, 2008, 5:30PM to 7:30PM in the ...
Rigel's R788 Phase 2a Results Published in Arthritis and Rheumatism
... drugs for the treatment of
inflammatory/autoimmune diseases and cancer, as well as viral and metabolic
diseases. Our pioneering research focuses on
intracellular signaling
pathways and related targets that are critical to disease mechanisms.
Rigel's productivity has resulted in strategic collaborations with ...
Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain
... developing therapeutic agents that act
through this mechanism. Ironwood's first cGMP modulator, linaclotide, acts
in the intestine to increase
intracellular and extracellular cGMP levels by
stimulating guanylate cyclase C. Linaclotide is currently being evaluated
in a comprehensive Phase 3 program by ...
Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
... of HPV-induced lesions. Interferon Alpha-2b is thought to
function by triggering an antiviral response within infected cells, by
activating certain
intracellular enzymes which cause degradation of viral
RNA, and by mobilizing the body's natural immune system to destroy the
infected cells. Interferon Alpha-2b ...
Cylex Announces Plan for Multi-Center Trial of ImmuKnow(R) Assay in South Korea
... at risk of infection or rejection of their transplant within 3
years of transplantation."
*Sanchez-Velasco P, Rodrigo E, Valero, R. et al.
intracellular ATP
concentrations of CD4 cells in kidney transplant patients with and without
infection. Clin Transplant. 2008;22:55-60.
About ImmuKnow(R)
...
SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines
... rationale for developing
PI3 kinase inhibitors to treat cancer. Phosphoinositide 3-kinase (PI3K) is
the gate keeper of one of the major pathways of
intracellular signal
transduction that regulates cell growth, proliferation, angiogenesis,
migration, differentiation, and survival. Dysregulation of the ...
Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors
... rationale for developing
PI3 kinase inhibitors to treat cancer. Phosphoinositide 3-kinase (PI3K) is
the gate keeper of one of the major pathways of
intracellular signal
transduction that regulates cell growth, proliferation, angiogenesis,
migration, differentiation, and survival. Dysregulation of the ...
Anavex presents neuroprotective effects of Anavex 1-41 at the International Conference on Alzheimer's Disease 2008
... of pro-amyloid and anti-amyloid theories of AD,
Anavex Life Sciences' SIGMACEPTOR(TM) Discovery Platform sigma-1 activator
molecules target neuronal
intracellular structures with the goal of
preventing neurodegenerative action of disturbed biochemical pathways and
channels.
About Anavex Life Sciences Corp.
...
Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
... This system enables the
functional delivery of siRNA molecules to targeted diseased tissues and
cells, while increasing their bioavailability and
intracellular uptake.
Silence's lead internal product, Atu027, is a proprietary AtuRNAi
molecule in preclinical development for systemic cancer indications. ...
Silence Therapeutics Announces Board Changes
... This system enables the
functional delivery of siRNA molecules to targeted diseased tissues and
cells, while increasing their bioavailability and
intracellular uptake.
Silence's lead internal product, Atu027, is a proprietary AtuRNAi
molecule in preclinical development for systemic cancer indications. ...
EntreMed Receives New Patent for 2-Methoxyestradiol Analogs
... Preclinical results demonstrate that certain analogs of 2ME2
can attack tumors on multiple fronts -- directly by disrupting
microtubules, an
intracellular matrix necessary for the rapid division of
cancer cells, through inhibition of mitosis and induction of apoptosis, and
by blocking blood vessels that ...
Preliminary Phase 2 Results of R788 in Lymphoma Show Benefit in Diffuse Large B-Cell and SLL/CLL
... drugs for the treatment of
inflammatory/autoimmune diseases and cancer, as well as viral and metabolic
diseases. Our pioneering research focuses on
intracellular signaling
pathways and related targets that are critical to disease mechanisms.
Rigel's productivity has resulted in strategic collaborations with ...
Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
... for proper insulin regulation,
which may enhance glucose homeostasis. GDIR stimulation has also been found
to increase the levels and activity of
intracellular factors thought to be
involved in the preservation of beta cells. The GDIR is amenable to small
molecule, orally active, drug development.
About ...
Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
... and other processes. PDX
was rationally designed for efficient transport into tumor cells via the
reduced folate carrier, or RFC-1, and effective
intracellular drug
retention. The Company believes these biochemical features, together with
preclinical and clinical data in a variety of tumors, suggest that PDX ...
Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
... proteins chemically linked at specific sites to
phosphates. This profile provides the Company with a proprietary and unique
window into the
intracellular action of CNS drugs or drug candidates.
Intra-Cellular Therapies uses this platform in its drug discovery and
development efforts of proprietary ...